International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Strok... (. regulatory authorities. ''Our ultimate...)

International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Stroke Recovery

Date:9/27/2007

. regulatory authorities. ''Our ultimate goal is to see NeuroAid(TM) included in key treatment guidelines for stroke victims, making its benefits available to all patients who need it,'' David added.

NeuroAid(TM)'s efficacy and safety was tested in a multi-centre double blind randomized clinical trial conducted on 605 patients in China in 1999- 2000. Patients taking NeuroAid(TM) were shown to be 2.11 times more likely to reach functional independence and 1.7 times more likely to reduce their neurological deficit by at least 55% than patients who did not take the product. It helped improve stroke patients' ability to recover even when treatment was started several weeks after the onset of stroke.

About NeuroAid(TM)

NeuroAid(TM) is a Traditional Chinese Medicine that provides faster and more extensive recovery of motor and cognitive functions in stroke patients during rehabilitation. It is a combination of fourteen all-natural ingredients from the Chinese medicinal pharmacopoeia, formulated according to international Good Manufacturing Practice (GMP) standards. It is marketed internationally by Moleac, the biopharmaceutical company that identified the product in China as the first medicine to help improve stroke recovery. NeuroAid(TM) is currently marketed in Singapore as a Chinese proprietary medicine, and in other countries in the region as a dietary supplement. It is also sold internationally by Moleac via the website http://www.neuroaid.com . With the CHIMES study, NeuroAid(TM) is the first traditional medicine in the world to be studied in a large scale evidence-based clinical trial.

About Moleac

Moleac is a biopharmaceutical company based in Biopolis, a world-class purpose built complex for biomedical sciences research in Singapore ( http://www.biopolis.com.sg ). Moleac identifies promising medicines discovered in China and dev
'/>"/>

SOURCE Moleac
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4
Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
6. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
7. Nuvelo Announces Presentations on rNAPc2 and NU172 at the XXIst Congress of the International Society on Thrombosis and Haemostasis
8. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
9. Labopharm to Present Poster on Dose Titration of Once-daily Tramadol at 3rd International Forum on Pain Medicine
10. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
11. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients

Post Your Comments:

(Date:3/17/2010)... the federal government and certain states to settle a whistleblower lawsuit that exposed an alleged kickback scheme by the pharmaceutical company to boost its sales of Kadian, a prescription painkiller. , ... , ... ... ...

(Date:3/17/2010)... 12 Cancer Drugs Tested, 20 Leading U.S. Cancer Centers Involved ,, ... , , ... ... ...

(Date:3/17/2010)... , North America ,s leading healthcare Network, has another solution for the down economy. , ... , ... ... ...

Breaking Medicine Technology:Whistleblower Kickback Case Against Alpharma Results In $42.5 Million Recovery for U.S. and States 2 Whistleblower Kickback Case Against Alpharma Results In $42.5 Million Recovery for U.S. and States 3 Agendia to Play Pivotal Role in ISPY-2 Trial for Breast Cancer 2 Agendia to Play Pivotal Role in ISPY-2 Trial for Breast Cancer 3 Agendia to Play Pivotal Role in ISPY-2 Trial for Breast Cancer 4 Agendia to Play Pivotal Role in ISPY-2 Trial for Breast Cancer 5 Healthcare Web Site Expands Reach to Pharmacy Industry 2 Healthcare Web Site Expands Reach to Pharmacy Industry 3 Healthcare Web Site Expands Reach to Pharmacy Industry 4 Jackson 26amp 3B Coker Investigates the Impact of Social Media on Hospitals and Physicians 59119 1 Jackson 26amp 3B Coker Investigates the Impact of Social Media on Hospitals and Physicians 59119 2 Jackson 26amp 3B Coker Investigates the Impact of Social Media on Hospitals and Physicians 59119 3 Jackson 26amp 3B Coker Investigates the Impact of Social Media on Hospitals and Physicians 59119 4 Jackson 26amp 3B Coker Investigates the Impact of Social Media on Hospitals and Physicians 59119 5 Chronic Fatigue Syndrome and Stem Cell Therapy Latest Research Available at CheneyResearch com 59116 1 Chronic Fatigue Syndrome and Stem Cell Therapy Latest Research Available at CheneyResearch com 59116 2 Chronic Fatigue Syndrome and Stem Cell Therapy Latest Research Available at CheneyResearch com 59116 3 Chinese Food and Drug Administration Approves Gabexate Mesylate as Pharmaceutical Raw Material 5315 1 Chinese Food and Drug Administration Approves Gabexate Mesylate as Pharmaceutical Raw Material 5315 2

[0] Whistleblower Kickback Case Against Alpharma Results In $42.5 Million Recovery for U.S. and States [0] Agendia to Play Pivotal Role in ISPY-2 Trial for Breast Cancer [0] Healthcare Web Site Expands Reach to Pharmacy Industry

... First-In-Human Study to Cancer Patients, SALT LAKE ... that its first-in-humans Phase 1 study of PRLX ... evaluate the safety,pharmacokinetic and pharmacodynamic properties of PRLX ... include TGen Clinical Research at,Scottsdale Healthcare in Scottsdale, ...

... Cancer Drug, CHAPEL HILL, N.C., Aug. 28 ... drug irinotecan, and the U.S. Food and Drug,Administration should ... at the University of North Carolina at Chapel,Hill. ... used mainly as a,second-line treatment for colorectal cancer, the ...

Other Medicine Technology:Prolexys Pharmaceuticals Initiates Phase 1 Study 2 DNA Test Predicts Harmful Effects of Cancer Drug 2

Prolexys Pharmaceuticals Initiates Phase 1 Study DNA Test Predicts Harmful Effects of Cancer Drug

(Date:3/18/2010)... , ... Newborn’s Life and Still Afford Flowers for your Mom , ... Westport, CT (Vocus) March 18, 2010 -- This Mother’s Day, Save the Children ... of the poorest, most remote communities in the world. For as little as $13 you ...

(Date:3/18/2010)... ... ... ... 18 Kids in Michigan will take center stage in the fight against tobacco on March 24 as they join thousands of young people nationwide for the ...

(Date:3/18/2010)... work/life solutions, today announced that it has been named to the Center for Companies That Care Honor Roll for the third straight year. , ... , ... ... ...

(Date:3/18/2010)... participating in shift work, especially those working rotating shifts, ... Syndrome (IBS) and abdominal pain compared to those working ... the American Journal of Gastroenterology . , "We ... of gastrointestinal symptoms such as abdominal pain, constipation and ...

(Date:3/18/2010)... ... Record (EHR) , ... (PRWEB) March 18, 2010 -- The American Society of Health Informatics Managers, Inc. ... The free application enables Health IT Consultants to help physicians select an Electronic ...

Breaking Medicine News(10 mins):Health News:A Mother's Day Gift that Gives Lasting Joy 2 Health News:Michigan Kids 'Kick Butts' on March 24 2 Health News:Michigan Kids 'Kick Butts' on March 24 3 Health News:Michigan Kids 'Kick Butts' on March 24 4 Health News:Michigan Kids 'Kick Butts' on March 24 5 Health News:Bright Horizons Honored as 'Company that Cares' for Third Straight Year 2 Health News:Bright Horizons Honored as 'Company that Cares' for Third Straight Year 3 Health News:Shift workers at more risk for irritable bowel syndrome, U-M study says 2 Health News:Health IT Consultants: EHR Vendor Directory – There's an App for That 2

[0] A Mother's Day Gift that Gives Lasting Joy [0] Michigan Kids 'Kick Butts' on March 24 [0] Bright Horizons Honored as 'Company that Cares' for Third Straight Year [0] Shift workers at more risk for irritable bowel syndrome, U-M study says [0] Health IT Consultants: EHR Vendor Directory – There's an App for That

... should be given a higher priority and more funding, ... people in Southeast Asia suffer from tropical diseases such ... emerging as another important problem in the region. ... have considerable economic impact on populations that are already ...

... of Patricia Rooper, who died following a 'delayed reaction' to ... has revealed that radiation had caused her death last year ... diagnosed with cancer of the left breast in 1971 when ... to intensive radiotherapy at Hammersmith hospital in London. There she ...

... The Russian government has approved a five-year, $2.9 billion ... in an effort to improve the country's life expectancy, ... ,According to the state statistics agency, Russia's population ... was recorded at 142.2 million -- a new post-Soviet ...

... and child-care groups are calling on the Federal Government to ... stomach bugs. ,Rotavirus puts 10,000 Australian children in ... emergency wards and at doctors' surgeries with symptoms of acute ... given to children aged six to 32 weeks, is only ...

... in the Journal of Clinical Oncology reveals there may ... of patients// with recurrent prostate cancer. ,This ... that scientists at Cedars-Sinai Medical Center in Los Angeles ... prostate cancer patients with no previous chemotherapy treatment. ...

... getting missed out in patients undergoing colonoscopy when it ... a surgeon. This was disclosed by a report published ... ,This study was conducted on 12,487 colorectal patients by ... her team. According to this study, new cases of ...

Other Medicine News:Health News:WHO Urges Higher Priority for Neglected Diseases 2 Health News:‘Delayed Reaction’ to Radiation Therapy Takes the Life of a Woman After 30 Yea 2 Health News:Russia Launches Five-Year Plan To Combat Diseases, Including TB, HIV/AIDS 2 Health News:Call for Rotavirus Vaccine Funding 2

WHO Urges Higher Priority for Neglected Diseases ‘Delayed Reaction’ to Radiation Therapy Takes the Life of a Woman After 30 Yea Russia Launches Five-Year Plan To Combat Diseases, Including TB, HIV/AIDS Call for Rotavirus Vaccine Funding Targeted Compound Helps Recurrent Prostate Cancer Patients Colorectal Cancer Getting Missed Out in Office Setting

... Eppendorf Reference Series 2000 Pipette is a ... a compact and robust design, and superior ... used to operate the measuring stroke and ... Product features:Eppendorf "pipette/tip" system ensures utmost accuracy ...

... Series 2000 Pipette is a synonym for ... and robust design, and superior operating comfort. ... operate the measuring stroke and blow-out as ... "pipette/tip" system ensures utmost accuracy and precision. ...

... is ideal for repeated pipetting ... volume FInnpipettes offer the same ... Finnpipette Digital pipettes: New, ... Soft-touch tip ejection, Safety label, ...

Medicine Products:

Eppendorf Reference Series 2000 Fixed-volume Pipette, 400 l Eppendorf Reference Series 2000 Fixed-volume Pipette, 750 l Eppendorf Reference Series 2000 Fixed-volume Pipette, 800 l Finnpipette Fixed Volume, 5000ul

International Expert Group Initiates Largest Multi-center Phase III Trial to Evaluate NeuroAid(TM) in Strok...(. regulatory authorities. ''Our ultimate...),Health